>>> US Gapping up

Gapping up
In reaction to strong earnings/guidance:

SGMO +39.1%, (also announced strategic collaboration with Pfizer), RELY +22.4%, CUR +15.3%, XONE +14.5%, CAAS +11.5%, PEGA +9.4%,LIVE +9.2%, LPSN +7.5%, CCXI +7.5%, STML +6.4%,XON +4.3%, QBAK +4.3%, PFIE +3.7%, ASM +3.2%,BSTG +3.2%, NTES +3.1%, BTX +3%, MGA +2.9%,WFM +2.8%, VUZI +2.7%, BAM +2.7%, SCLN +2.6%,GALE +2.6%, INO +2.5%, CALL +2.5%, AYX +2.5%,CORI +2.5%, HIMX +2.2%, EEP +2%, FBIO +1.9%, OA +1.9%, ATH +1.8%, ICUI +1.7%, TTGT +1.7%, SNDR +1.6%, RUN +1.2%, CDEV +1.2%, PCYG +1.2%, CBIO +1.2%

M&A news:

Select metals/mining stocks trading higher:

GFI +1.8%, GOLD +1.7%, AU +1.6%, SSRI +1.4%, AG+1.3%, FCX +1.3%, GDX +0.8%, RIO +0.8%, BBL +0.7%

Other news:

SYN +35.4% (FDA has granted a Breakthrough Therapy Designation for SYN-004)
PED +34% (continued strength)
SYMX +25.8% (enters into a Technology License Agreement with Australian Future Energy for a large-scale project to be located in Australia)
IPCI +6.8% (receives final FDA approval for its ANDA for quetiapine fumarate extended-release tablets)
MRK +2.7% (confirms FDA approval of KEYTRUDA (pembrolizumab) as first-line combination therapy with pemetrexed and carboplatin for patients with metastatic NSCLC irrespective of PD-L1 expression)
NMM +2.3% (provides update for acquisition of 14-Vessel container fleet from Rickmers Maritime)
ORLY +1% (to increase the authorization amount under its share repurchase program by an additional $1 billion, raising the aggregate authorization under the program to $8.75 billion)
MYL +1% (in sympathy with TEVA)

Analyst comments: